Gilead Sciences Reports Phase 3 Switch Study Results for Biktarvy in HIV Treatment

Gilead Sciences today announced Phase 3 switch study results for Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in virologically suppressed adults with HIV-1. The studies demonstrated that patients who switched to Biktarvy from other regimens maintained high rates of viral suppression at 48 weeks, with no treatment-emergent resistance observed.